Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024
Clearside Biomedical (Nasdaq: CLSD), a biopharmaceutical company specializing in suprachoroidal space (SCS®) therapies for eye conditions, has announced its schedule for reporting second quarter 2024 financial results. The company will release its Q2 2024 financials on Monday, August 12, 2024, after the financial markets close. Notably, Clearside has opted not to hold a Q2 2024 conference call. Instead, they recently hosted a Suprachoroidal Delivery Key Opinion Leader Webinar on July 24, 2024, with a replay available on their website. The company plans to resume quarterly earnings conference calls starting with the third quarter 2024 financial results.
Clearside Biomedical (Nasdaq: CLSD), un'azienda biomedica specializzata in terapie per lo spazio suprachoroidale (SCS®) per condizioni oculari, ha annunciato il programma per la comunicazione dei risultati finanziari del secondo trimestre 2024. L'azienda pubblicherà i risultati finanziari del Q2 2024 lunedì 12 agosto 2024, dopo la chiusura dei mercati finanziari. È importante notare che Clearside ha deciso di non tenere una conferenza telefonica per il secondo trimestre 2024. Invece, hanno recentemente organizzato un Webinar per Leader di Opinione sulla Somministrazione Suprachoroidale il 24 luglio 2024, con un replay disponibile sul loro sito web. L'azienda prevede di riprendere le conferenze telefoniche trimestrali sugli utili a partire dai risultati finanziari del terzo trimestre 2024.
Clearside Biomedical (Nasdaq: CLSD), una empresa biofarmacéutica especializada en terapias para el espacio suprachoroideo (SCS®) para condiciones oculares, ha anunciado su calendario para informar sobre los resultados financieros del segundo trimestre de 2024. La compañía publicará sus resultados financieros del Q2 2024 el lunes 12 de agosto de 2024, después del cierre de los mercados financieros. Cabe destacar que Clearside ha optado por no realizar una conferencia telefónica para el Q2 2024. En su lugar, recientemente llevaron a cabo un Webinar para Líderes de Opinión sobre la Administración Suprachoroidea el 24 de julio de 2024, con una repetición disponible en su sitio web. La empresa planea reanudar las conferencias telefónicas trimestrales de ganancias a partir de los resultados financieros del tercer trimestre de 2024.
클리어사이드 생물의학(Clearside Biomedical, Nasdaq: CLSD)은 안질환을 위한 망막 장막 공간(SCS®) 치료를 전문으로 하는 생물제약 회사입니다. 이 회사는 2024년 2분기 재무 실적을 보고할 일정을 발표했습니다. 클리어사이드는 2024년 8월 12일 월요일, 금융 시장 마감 후에 2분기 재무 실적을 발표할 예정입니다. 특히 클리어사이드는 2024년 2분기 회의 전화를 진행하지 않기로 결정했습니다. 대신, 그들은 망막 장막 전달 주요 의견 리더 웨비나를 2024년 7월 24일에 개최하였으며, 리플레이는 그들의 웹사이트에서 제공됩니다. 이 회사는 2024년 3분기 재무 실적부터 분기별 수익 회의 전화를 재개할 계획입니다.
Clearside Biomedical (Nasdaq: CLSD), une entreprise biopharmaceutique spécialisée dans les thérapies pour l'espace suprachoroïdal (SCS®) pour les affections oculaires, a annoncé son calendrier pour le rapport des résultats financiers du deuxième trimestre 2024. La société publiera ses résultats financiers du Q2 2024 le lundi 12 août 2024, après la fermeture des marchés financiers. Il est à noter que Clearside a choisi de ne pas tenir de conférence téléphonique pour le Q2 2024. À la place, ils ont récemment organisé un Webinaire pour Leaders d'Opinion sur l'Administration Suprachoroïdale le 24 juillet 2024, avec un replay disponible sur leur site web. L'entreprise prévoit de recommencer les conférences téléphoniques trimestrielles sur les bénéfices à partir des résultats financiers du troisième trimestre 2024.
Clearside Biomedical (Nasdaq: CLSD), ein biopharmazeutisches Unternehmen, das sich auf Therapien für den suprachoroidalen Raum (SCS®) bei Augenkrankheiten spezialisiert hat, hat seinen Zeitplan für die Berichterstattung über die Finanzergebnisse des zweiten Quartals 2024 bekannt gegeben. Das Unternehmen wird seine Finanzergebnisse für das 2. Quartal 2024 am Montag, den 12. August 2024, nach Börsenschluss veröffentlichen. Auffällig ist, dass Clearside beschlossen hat, keine Telefonkonferenz für das 2. Quartal 2024 abzuhalten. Stattdessen haben sie kürzlich ein Webinar für Schlüsselmeinungsführer zur suprachoroidalen Verabreichung am 24. Juli 2024 veranstaltet, dessen Aufzeichnung auf ihrer Website verfügbar ist. Das Unternehmen plant, die vierteljährlichen Gewinnkonferenzen mit den Finanzergebnissen des dritten Quartals 2024 wieder aufzunehmen.
- Timely reporting of Q2 2024 financial results scheduled
- Proactive investor communication through Key Opinion Leader Webinar
- Plans to resume regular quarterly earnings calls from Q3 2024
- None.
ALPHARETTA, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its second quarter 2024 financial results will be reported on Monday, August 12, 2024, after the close of the financial markets.
In lieu of a second quarter 2024 conference call, the Company hosted a Suprachoroidal Delivery Key Opinion Leader Webinar on Wednesday, July 24, 2024. The replay of this event is available on the Clearside website under the Investors section: Events and Presentations. Quarterly earnings conference calls are expected to resume with the third quarter 2024 financial results.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com and follow us on LinkedIn and X.
Investor and Media Contacts:
Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206
Source: Clearside Biomedical, Inc.
FAQ
When will Clearside Biomedical (CLSD) report its Q2 2024 financial results?
Will Clearside Biomedical (CLSD) hold a conference call for Q2 2024 results?
When will Clearside Biomedical (CLSD) resume regular quarterly earnings calls?
Where can I find the replay of Clearside Biomedical's (CLSD) recent Key Opinion Leader Webinar?
